1. Name and Address of Reporting Person
   RICHMOND TIMOTHY J.  
   (Last) (First) (Middle)
   1 N. WAUKEGAN ROAD

2. Issuer Name and Ticker or Trading Symbol
   AbbVie Inc. [ABBV]

3. Date of Earliest Transaction (Month/Day/Year)
   12/06/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)
   -

5. Relationship of Reporting Person(s) to Issuer
   -
   Director
   10% Owner
   EVP, Chief HR Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
   -
   Form filed by One Reporting Person
   Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 4, 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, $0.01 par value</td>
<td>12/06/2021</td>
<td></td>
<td>M</td>
<td>50,350 A</td>
<td>50,350 D</td>
<td>Direct</td>
<td>-</td>
</tr>
<tr>
<td>Common Stock, $0.01 par value</td>
<td>12/06/2021</td>
<td></td>
<td>S</td>
<td>50,350 D</td>
<td>120 D</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security Beneficially Owned Following Report Date Transaction(s) (Instr. 4)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Report Date Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Option (Right to buy)</td>
<td>$58.88</td>
<td>12/06/2021</td>
<td></td>
<td>M</td>
<td>50,350 (A)</td>
<td>02/19/2016 02/18/2025</td>
<td>Common stock</td>
<td>50,350 D</td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:
This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Steven L. Scrogum, attorney-in-fact for Timothy J. Richmond  
12/06/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Note: File three copies of this Form, one of which must be manually signed, if space is insufficient, use another sheet and attach the copies.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.